---
figid: PMC9204593__fcvm-09-904881-g002
figtitle: Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin
  Receptor-Neprilysin Inhibitors in Patients With Heart Failure
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Ovis aries
pmcid: PMC9204593
filename: fcvm-09-904881-g002.jpg
figlink: /pmc/articles/PMC9204593/figure/F2/
number: F2
caption: Mechanisms of action of novel therapeutics for heart failure. The ARNi LCZ696
  is split into the ARB valsartan and the neprilysin-inhibitor sacubitril. Valsartan
  abrogates signaling via the AT1 receptor, inhibiting deleterious effects mediated
  by Ang-II such as vasoconstriction, hypertrophy, and fibrosis in major cardiovascular
  organs. Sacubitril prevents breakdown of endogenous natriuretic peptides (ANP, BNP,
  and CNP), thereby augmenting their beneficial actions in cardiovascular disease.
  The overall effects of ARNi are vasodilatation, natriuresis, and diuresis, as well
  as inhibition of fibrosis and hypertrophy. Ularitide selectively targets NPR-A,
  whereas cenderitide activates both NPR-A and NPR-B. Both peptides increase intracellular
  cGMP, which in turn leads to inhibition of the renin-angiotensin-aldosterone system
  and attenuation of fibrosis, hypertrophy, and vasoconstriction. Our proposed model
  shows that TRPV1 interacting with NPR-A, activation of the NPR1 and ANP pathway
  leads to cGMP-dependent stimulation ofTRPV1 phosphorylation. PDE3 antagonists (enoximone,
  milrinone), calcium sensitizers (levosimendan), and a direct activator of cardiac
  myosin (omecamtiv mecarbil). ACE, angiotensin-converting enzyme; TRPV1, transient
  receptor potential cation channel subfamily V member 1; Ang-I/II, angiotensin I/II;
  ARB, angiotensin-receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor;
  AT1, type-1 angiotensin II receptor; ANP, A-type natriuretic peptide; BNP, B-type
  natriuretic peptide; CNP, C-type natriuretic peptide; NPR-A/B, atrial natriuretic
  peptide receptor 1/2; PDE3, phosphodiesterase-3; pGC, plasma- membrane-bound guanylate
  cyclase; PKA, protein kinase A; PKC, protein kinase C; PKG, protein kinase G; pGC,
  plasma- membrane-bound guanylate cyclase; sGC, soluble guanylate cyclase.
papertitle: Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin
  Receptor-Neprilysin Inhibitors in Patients With Heart Failure.
reftext: Kun Ding, et al. Front Cardiovasc Med. 2022;9:904881.
year: '2022'
doi: 10.3389/fcvm.2022.904881
journal_title: Frontiers in Cardiovascular Medicine
journal_nlm_ta: Front Cardiovasc Med
publisher_name: Frontiers Media S.A.
keywords: transient receptor potential cation channel subfamily V member 1 | transient
  receptor potential cation channel subfamily C member 6 | natriuretic peptide | heart
  failure | angiotensin receptor-neprilysin inhibitor (ARNI)
automl_pathway: 0.9195266
figid_alias: PMC9204593__F2
figtype: Figure
organisms_ner:
- Mus musculus
- Ovis aries
- Homo sapiens
- Rattus norvegicus
redirect_from: /figures/PMC9204593__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9204593__fcvm-09-904881-g002.html
  '@type': Dataset
  description: Mechanisms of action of novel therapeutics for heart failure. The ARNi
    LCZ696 is split into the ARB valsartan and the neprilysin-inhibitor sacubitril.
    Valsartan abrogates signaling via the AT1 receptor, inhibiting deleterious effects
    mediated by Ang-II such as vasoconstriction, hypertrophy, and fibrosis in major
    cardiovascular organs. Sacubitril prevents breakdown of endogenous natriuretic
    peptides (ANP, BNP, and CNP), thereby augmenting their beneficial actions in cardiovascular
    disease. The overall effects of ARNi are vasodilatation, natriuresis, and diuresis,
    as well as inhibition of fibrosis and hypertrophy. Ularitide selectively targets
    NPR-A, whereas cenderitide activates both NPR-A and NPR-B. Both peptides increase
    intracellular cGMP, which in turn leads to inhibition of the renin-angiotensin-aldosterone
    system and attenuation of fibrosis, hypertrophy, and vasoconstriction. Our proposed
    model shows that TRPV1 interacting with NPR-A, activation of the NPR1 and ANP
    pathway leads to cGMP-dependent stimulation ofTRPV1 phosphorylation. PDE3 antagonists
    (enoximone, milrinone), calcium sensitizers (levosimendan), and a direct activator
    of cardiac myosin (omecamtiv mecarbil). ACE, angiotensin-converting enzyme; TRPV1,
    transient receptor potential cation channel subfamily V member 1; Ang-I/II, angiotensin
    I/II; ARB, angiotensin-receptor blocker; ARNi, angiotensin receptor-neprilysin
    inhibitor; AT1, type-1 angiotensin II receptor; ANP, A-type natriuretic peptide;
    BNP, B-type natriuretic peptide; CNP, C-type natriuretic peptide; NPR-A/B, atrial
    natriuretic peptide receptor 1/2; PDE3, phosphodiesterase-3; pGC, plasma- membrane-bound
    guanylate cyclase; PKA, protein kinase A; PKC, protein kinase C; PKG, protein
    kinase G; pGC, plasma- membrane-bound guanylate cyclase; sGC, soluble guanylate
    cyclase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ace
  - Ang3
  - Angpt1
  - Ang
  - Tm7sf2
  - Agt
  - Od
  - Npr1
  - Pgc
  - Nt5c2
  - Cnp
  - Nppc
  - S100a11
  - Fblim1
  - Gopc
  - Car1
  - Pdia4
  - ap
  - App
  - H2-Ab1
  - Tnfrsf11a
  - ACE
  - ANG-1
  - ANGPT1
  - ITGAX
  - NPR1
  - PGC
  - CNP
  - NPPC
  - CA1
  - TM7SF2
  - BEST1
  - PRKG1
  - ATP8A2
  - APRT
  - MFAP1
  - NPR2
  - NT5C2
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - FBLIM1
  - GOPC
  - MYH14
  - MYO6
  - MYO10
  - MYO16
  - MYO19
  - MYH1
  - MYH10
  - MYH11
  - MYH13
  - MYH15
  - MYH16
  - MYH2
  - MYH3
  - MYH4
  - MYH6
  - MYH7
  - MYH7B
  - MYH8
  - MYH9
  - MYO1A
  - MYO1B
  - MYO1C
  - MYO1D
  - MYO1E
  - MYO1F
  - MYO1G
  - MYO1H
  - MYO3A
  - MYO3B
  - MYO5A
  - MYO5B
  - MYO5C
  - MYO7A
  - MYO7B
  - MYO9A
  - MYO9B
  - MYO15A
  - MYO15B
  - MYO18A
  - MYO18B
  - MYL1
  - MYL3
  - MYL4
  - MYL6
  - MYL6B
  - MYL10
  - MYL12A
  - MYL12B
  - MYL2
  - MYL5
  - MYL7
  - MYL9
  - MYL11
  - MTG1
  - APP
  - SUCLA2
  - TNFRSF11A
  - Tmprss5
  - Npr2
  - Pck1
---
